Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Shares Outstanding (Diluted Average): 2019-2025

Historic Shares Outstanding (Diluted Average) for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to $66.3 million.

  • Rhythm Pharmaceuticals' Shares Outstanding (Diluted Average) rose 8.23% to $66.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.3 million, marking a year-over-year increase of 8.23%. This contributed to the annual value of $61.0 million for FY2024, which is 5.76% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Shares Outstanding (Diluted Average) stood at $66.3 million for Q3 2025, which was up 4.05% from $63.7 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $66.3 million during Q3 2025, and registered a low of $48.5 million during Q1 2021.
  • Over the past 3 years, Rhythm Pharmaceuticals' median Shares Outstanding (Diluted Average) value was $61.0 million (recorded in 2024), while the average stood at $60.5 million.
  • Data for Rhythm Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY increased of 13.86% (in 2021) over the last 5 years.
  • Over the past 5 years, Rhythm Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarterly) stood at $49.6 million in 2021, then climbed by 5.08% to $52.1 million in 2022, then increased by 10.65% to $57.7 million in 2023, then rose by 5.76% to $61.0 million in 2024, then increased by 8.23% to $66.3 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $66.3 million for Q3 2025, versus $63.7 million for Q2 2025 and $63.1 million for Q1 2025.